Crossmark

Efficacy and safety of immune checkpoint inhibitors for locoregionally advanced, recurrent and metastatic nasopharyngeal carcinoma: a systematic review of phase III randomised controlled trials

Crossref DOI link: https://doi.org/10.1007/s00210-025-04572-3

Published Online: 2025-09-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Manoharan, Sivananthan

Ying Ying, Lee
Funding

Funding for this research was provided by:

Kementerian Kesihatan Malaysia (NMRR-24-01431-SXW)
License Information

Text and Data Mining valid from 2025-09-15

Version of Record valid from 2025-09-15
More Information

Article History

Received: 3 June 2025

Accepted: 19 August 2025

First Online: 15 September 2025

Declarations

:

: Not applicable.

: Not applicable.

: Director General of Health Malaysia has given his permission to publish this article.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below